Immunopurified clotting factor concentrates.
Monoclonally purified factor concentrates have been available for hemophilia treatment since the late 1980's. They are biochemically characterized by a high-degree of clotting factor (FVIII or FIX) purification and by the virtual lack of contaminants (immunoglobulins, fibrinogen and fibronectin). The purification procedure sharply reduces the viral load and increases the safety of the concentrate because of the viral inactivation procedures. Viral safety is demonstrated by prospective studies in previously untreated patients as well as by the huge amount of concentrates produced and used so far without reports of untoward side effects. Monoclonal concentrates are also safe in terms of inhibitor production: they do not elicit the appearance of inhibitors to either FVIII or FIX with increased frequency, as shown by data in published prospective studies. Prospective studies have recently demonstrated that the long-term administration of these high purity concentrates does not exert any side effects on the immune system in HIV-positive hemophiliacs. The FIX concentrate is also extremely safe in terms of thrombotic complications: the highly pure FIX does not activate blood coagulation. It has been shown that the monoclonally purified FIX concentrate caused no thrombotic events in high-risk surgical patients who had previously experienced such complications while on Prothrombin Complex Concentrates.
Mariani
G
G
Department of Human Biopathology, University of Rome La Sapienza, Italy.
Di Nucci
G D
GD
Arcieri
P
P
D000911:Antibodies, Monoclonal; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000302:isolation & purification* / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy; D006801:Humans
D000911:Antibodies, Monoclonal; D001779:Blood Coagulation Factors